Patents by Inventor Yu Tian Wang
Yu Tian Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220362326Abstract: Disclosed herein are uses of a polypeptide comprising NIMoEsh to treat a disease or condition associated with acute myocardial infarction (AMI) in a subject in need thereof, of a polypeptide comprising NIMoEsh to restore heart function after AMI in a subject in need thereof, of a polypeptide comprising NIMoEsh to reduce or prevent AMI-induced heart function loss in a subject in need thereof, of a polypeptide comprising NIMoEsh to reduce AMI-induced heart tissue infarct in a subject in need thereof, and of a polypeptide comprising NIMoEsh to protect cardiomyocytes against AMI-induced function loss in a subject in need thereof. Disclosed also herein are methods by which such treating, restoring, reducing or preventing, reducing, and/or protecting may be done, and a polypeptide comprising NIMoEsh for use in such treating, restoring, reducing or preventing, reducing, and/or protecting.Type: ApplicationFiled: September 11, 2020Publication date: November 17, 2022Applicant: The University of British ColumbiaInventors: Jack Wuyang Jin, Yu Tian Wang, Max S. Cynader
-
Publication number: 20220056088Abstract: In one aspect, the invention provides a peptide comprising a chaperone-mediated autophagy (CMA)-targeting signal domain; a protein-binding domain that selectively binds to a target cytosolic protein; and a cell membrane penetrating domain (CMPD). In another aspect, the invention provides methods for reducing the intracellular expression level of an endogenous target protein in vitro and in an animal, wherein the method involves administration of the peptide. Methods are also provided for treating a pathological condition in an animal, the methods comprising administering the peptide to the animal. In one embodiment, the pathological condition is a neurodegenerative disease. In another embodiment of the invention, the target cytosolic protein is death associated protein kinase 1 and the CMPD is protein transduction domain of the HIV-1 Tat protein.Type: ApplicationFiled: November 5, 2021Publication date: February 24, 2022Inventors: Yu Tian Wang, Xuelai Fan, Jack Wuyang Jin
-
Patent number: 11186620Abstract: In one aspect, the invention provides a peptide comprising a chaperone-mediated autophagy (CMA)-targeting signal domain; a protein-binding domain that selectively binds to a target cytosolic protein; and a cell membrane penetrating domain (CMPD). In another aspect, the invention provides methods for reducing the intracellular expression level of an endogenous target protein in vitro and in an animal, wherein the method involves administration of the peptide. Methods are also provided for treating a pathological condition in an animal, the methods comprising administering the peptide to the animal. In one embodiment, the pathological condition is a neurodegenerative disease. In another embodiment of the invention, the target cytosolic protein is death associated protein kinase I and the CMPD is protein transduction domain of the HIV-1 Tat protein.Type: GrantFiled: March 27, 2019Date of Patent: November 30, 2021Assignee: University of British ColumbiaInventors: Yu Tian Wang, Xuelai Fan, Jack Wuyang Jin
-
Patent number: 11166924Abstract: This invention relates to therapeutic compounds and compositions, and methods for their use in the prevention or treatment of neurological disorders. In particular, the invention relates to N-methyl-D-aspartate receptor (NMDAR) allosteric modulators and methods for their use in the prevention or treatment of disorders or conditions caused by or related to NMDAR dysfunctions. The invention also relates to a method for identifying NMDAR allosteric modulators.Type: GrantFiled: September 26, 2017Date of Patent: November 9, 2021Assignee: Qingdao Primedicine Pharmaceutical Company, Ltd.Inventors: Yu Tian Wang, Peter Axerio-Cilies
-
Patent number: 11117939Abstract: The present application provides compositions, methods, and uses of polypeptide or antibody inhibitors of insig-1 ubiquitination for preventing or treating skin diseases or conditions associated with overproduction of sebum, such as acne and seborrhea.Type: GrantFiled: May 27, 2016Date of Patent: September 14, 2021Assignee: University of SasketchewanInventors: Changiz Taghibiglou, Yu Tian Wang
-
Publication number: 20190315819Abstract: In one aspect, the invention provides a peptide comprising a chaperone-mediated autophagy (CMA)-targeting signal domain; a protein-binding domain that selectively binds to a target cytosolic protein; and a cell membrane penetrating domain (CMPD). In another aspect, the invention provides methods for reducing the intracellular expression level of an endogenous target protein in vitro and in an animal, wherein the method involves administration of the peptide. Methods are also provided for treating a pathological condition in an animal, the methods comprising administering the peptide to the animal. In one embodiment, the pathological condition is a neurodegenerative disease. In another embodiment of the invention, the target cytosolic protein is death associated protein kinase 1 and the CMPD is protein transduction domain of the HIV-1 Tat protein.Type: ApplicationFiled: March 27, 2019Publication date: October 17, 2019Inventors: Yu Tian Wang, Xuelai Fan, Jack Wuyang Jin
-
Publication number: 20190216753Abstract: This invention relates to therapeutic compounds and compositions, and methods for their use in the prevention or treatment of neurological disorders. In particular, the invention relates to N-methyl-D-aspartate receptor (NMDAR) allosteric modulators and methods for their use in the prevention or treatment of disorders or conditions caused by or related to NMDAR dysfunctions. The invention also relates to a method for identifying NMDAR allosteric modulators.Type: ApplicationFiled: September 26, 2017Publication date: July 18, 2019Applicant: Qingdao Primedicine Pharmaceutical Company, Ltd.Inventors: Yu Tian Wang, Peter Axerio-Cilies
-
Patent number: 10287333Abstract: In one aspect, the invention provides a peptide comprising a chaperone-mediated autophagy (CMA)-targeting signal domain; a protein-binding domain that selectively binds to a target cytosolic protein; and a cell membrane penetrating domain (CMPD). In another aspect, the invention provides methods for reducing the intracellular expression level of an endogenous target protein in vitro and in an animal, wherein the method involves administration of the peptide. Methods are also provided for treating a pathological condition in an animal, the methods comprising administering the peptide to the animal. In one embodiment, the pathological condition is a neurodegenerative disease. In another embodiment of the invention, the target cytosolic protein is death associated protein kinase 1 and the CMPD is protein transduction domain of the HIV-1 Tat protein.Type: GrantFiled: September 27, 2013Date of Patent: May 14, 2019Assignee: University of British ColumbiaInventors: Yu Tian Wang, Xuelai Fan, Jack Wuyang Jin
-
Patent number: 10258666Abstract: Described herein are isolated polypeptides having phosphatase and tensin homolog (PTEN) inhibitory activity, vectors and cells for the expression thereof and methods for their use in treating diseases associated with cytotoxic stress, such as spinal cord injury, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease.Type: GrantFiled: July 27, 2015Date of Patent: April 16, 2019Assignee: The University of British ColumbiaInventors: Yu Tian Wang, Shu Zhang, Changiz Taghibiglou
-
Publication number: 20180305419Abstract: The present application provides compositions, methods, and uses of polypeptide or antibody inhibitors of insig-1 ubiquitination for preventing or treating skin diseases or conditions associated with overproduction of sebum, such as acne and seborrhea.Type: ApplicationFiled: May 27, 2016Publication date: October 25, 2018Inventors: Changiz Taghibiglou, Yu Tian Wang
-
Patent number: 9486472Abstract: Methods and compositions for treating neurological damage or dysfunction are described, including methods implemented by administration of peptide inhibitors of AMPA receptor endocytosis.Type: GrantFiled: April 22, 2011Date of Patent: November 8, 2016Assignee: UNIVERSITY OF BRITISH COLUMBIA CANADAInventors: Yu Tian Wang, Yushan Wang, Anthony Phillips, Lidong Liu, Yitao Liu
-
Publication number: 20160074472Abstract: Described herein are isolated polypeptides having phosphatase and tensin homolog (PTEN) inhibitory activity, vectors and cells for the expression thereof and methods for their use in treating diseases associated with cytotoxic stress, such as spinal cord injury, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease.Type: ApplicationFiled: July 27, 2015Publication date: March 17, 2016Inventors: Yu Tian Wang, Shu Zhang, Changiz Taghibiglou
-
Publication number: 20150266935Abstract: In one aspect, the invention provides a peptide comprising a chaperone-mediated autophagy (CMA)-targeting signal domain; a protein-binding domain that selectively binds to a target cytosolic protein; and a cell membrane penetrating domain (CMPD). In another aspect, the invention provides methods for reducing the intracellular expression level of an endogenous target protein in vitro and in an animal, wherein the method involves administration of the peptide. Methods are also provided for treating a pathological condition in an animal, the methods comprising administering the peptide to the animal. In one embodiment, the pathological condition is a neurodegenerative disease. In another embodiment of the invention, the target cytosolic protein is death associated protein kinase 1 and the CMPD is protein transduction domain of the HIV-1 Tat protein.Type: ApplicationFiled: September 27, 2013Publication date: September 24, 2015Applicant: University of British ColumbiaInventors: Yu Tian Wang, Shelly Xuelai Lan, Wuyang Jin Jin
-
Patent number: 9127079Abstract: Described herein are isolated polypeptides having phosphatase and tensin homolog (PTEN) inhibitory activity, vectors and cells for the expression thereof and methods for their use in treating diseases associated with cytotoxic stress, such as spinal cord injury, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease.Type: GrantFiled: October 15, 2010Date of Patent: September 8, 2015Assignee: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Yu Tian Wang, Shu Zhang, Changiz Taghibiglou
-
Publication number: 20120269829Abstract: Described herein are isolated polypeptides having phosphatase and tensin homolog (PTEN) inhibitory activity, vectors and cells for the expression thereof and methods for their use in treating diseases associated with cytotoxic stress, such as spinal cord injury, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease.Type: ApplicationFiled: October 15, 2010Publication date: October 25, 2012Inventors: Yu Tian Wang, Shu Zhang, Changiz Taghibiglou
-
Publication number: 20120077751Abstract: The invention provides, in part, methods and reagents for modulating neuronal apoptosis and for modulating synaptic plasticity.Type: ApplicationFiled: April 22, 2011Publication date: March 29, 2012Inventors: Yu Tian Wang, Yushan Wang, Anthony Phillips, Lidong Liu, Yitao Liu
-
Publication number: 20100048653Abstract: In various aspects, the invention provides methods and compositions for modulating NMDA receptor subtype activity, to enhance NR2A-containing NMDA receptor activity relative to NR2B-containing NMDA receptor activity, so as to effect a neuroprotective reduction in excitotoxic NMDA receptor activityType: ApplicationFiled: July 14, 2006Publication date: February 25, 2010Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Yu Tian Wang, Yitao Liu, Tak Pan Wong, Lidong Liu